What is Halozyme Therapeutics Inc (HALO)?
Halozyme Therapeutics Inc is a biotechnology company specializing in the development and commercialization of novel oncology therapies and drug delivery technologies. The company focuses on enhancing the efficacy and administration of cancer treatments through its proprietary enzyme technology, which modifies the extracellular matrix to improve drug penetration and absorption. Halozyme's platform is utilized both in its own therapeutic candidates and through partnerships with other pharmaceutical companies. The company operates in the biopharmaceutical sector, emphasizing innovation in drug delivery to address unmet medical needs. Its research and development efforts include the exploration of treatments for various cancers and other diseases, leveraging its enzymatic technology to facilitate subcutaneous administration of biologics. Halozyme Therapeutics collaborates with multiple industry partners to advance its pipeline and expand the application of its technology across different therapeutic areas. The company is headquartered in the United States and contributes to the broader field of oncology and drug delivery science.
Halozyme Therapeutics Inc Stock Price Today: Live Overview
The price today is shaped by intraday trading dynamics, with RXO Inc's value at $63.53. It is fluctuating within a range from $62.33 to $63.73, with a daily change of 0%.
FAQ: Halozyme Therapeutics Inc (HALO)
What is the current price of HALO stock?
The current price is $63.53.
Does HALO pay dividends?
Halozyme Therapeutics Inc pays dividends via cash distributions (if applicable).
Does HALO have a formal corporate presence or regional headquarters in the UAE?
Halozyme Therapeutics Inc has an official presence in the UAE, including offices in Dubai Internet City.
What is HALO best known for?
The company is most famous for its drug delivery technology and enzyme-based therapies.
What assets are typically shown together with HALO?
Commonly shown alongside HALO: Amundi PEA MSCI USA ESG Selection UCITS ETF, WaVe Life Sciences Ltd, Citi Trends
Latest shares articles



